News Releases

January 9, 2014

RepliCel Life Sciences to Present at Biotech Showcase™ 2014
Vancouver, Canada – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP), a clinical stage biopharmaceutical company focused on developing therapies... Read full article

January 9, 2014

RepliCel to Commence Trading on the TSX Venture Exchange
VANCOUVER, BC – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP) is pleased to announce that its common shares are... Read full article

January 2, 2014

RepliCel Announces Conditional Approval from TSX Venture Exchange
VANCOUVER, BC – January 2, 2014 –RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (CNSX: RP) is pleased to announce that it has received... Read full article

December 19, 2013

RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
VANCOUVER, BC – December 19, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP) today reported on the progress of its technology transfer agreement... Read full article

November 20, 2013

RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update
VANCOUVER, BC – November 20, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP), a clinical stage regenerative medicine company focused on the... Read full article

October 30, 2013

RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis
VANCOUVER, BC – October 30, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP),  a clinical stage biopharmaceutical company focused on the development of... Read full article

September 6, 2013

RepliCel Announces Stock Option Grant
VANCOUVER, BC – September 6, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development... Read full article

September 4, 2013

RepliCel Retains Westwicke Partners as Investor Relations Counsel
VANCOUVER, BC – September 4, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development... Read full article

July 19, 2013

RepliCel Announces Closing of Private Placement
VANCOUVER, BC – April 10, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF and CNSX: RP),  is pleased to announce... Read full article

July 11, 2013

Replicel and Shiseido Complete Collaboration and Technology Transfer Agreement on Technology for Treating Pattern Baldness
VANCOUVER, BC – July 11, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) is pleased to report that it has... Read full article